Talis Biomedical Corp

Company Profile

Talis Biomedical Corp had its IPO on 2021-02-12 under the ticker symbol TLIS.

The company operates in the Healthcare sector and Medical Devices industry. Talis Biomedical Corp has a staff strength of 102 employees.

Stock update

Shares of Talis Biomedical Corp opened at $6.07 at the start of the last trading session i.e. 2023-09-12.

The stocks traded within a range of $6.07 - $6.48, and closed at $6.45.

This is a +11.21% increase from the previous day's closing price.

A total volume of 4,687 shares were traded at the close of the day’s session.

In the last one week, shares of Talis Biomedical Corp have increased by +7.14%.

Talis Biomedical Corp's Key Ratios

Talis Biomedical Corp has a market cap of $10.82 million, indicating a price to book ratio of 0.0932 and a price to sales ratio of 2.7064.

In the last 12-months Talis Biomedical Corp’s revenue was $2.85 million with a gross profit of $-149398000 and an EBITDA of $-78865000. The EBITDA ratio measures Talis Biomedical Corp's overall financial performance and is widely used to measure its profitability.

In the trailing 12-month period, Talis Biomedical Corp’s operating margin was -3039.76% while its return on assets stood at -31.43% with a return of equity of -62.83%.

In Q2, Talis Biomedical Corp’s quarterly earnings growth was a positive 0% while revenue growth was a positive 1.6%.

Talis Biomedical Corp’s PE and PEG Ratio

Forward PE

0

Trailing PE

0

PEG

Its diluted EPS in the last 12-months stands at $-46.46 per share while it has a forward price to earnings multiple of 0 and a PEG multiple of . A low price to earnings ratio can mean the stock is attractively valued while a high ratio suggests the stock may be overvalued.

The PEG on the other hand provides a broader view compared to the P/E ratio and gives greater insight into Talis Biomedical Corp’s profitability.

Talis Biomedical Corp stock is trading at a EV to sales ratio of 14.5685 and a EV to EBITDA ratio of 0.8804. Its price to sales ratio in the trailing 12-months stood at 2.7064.

Talis Biomedical Corp stock pays annual dividends of $0 per share, indicating a yield of 0% and a payout ratio of 0%.

Balance sheet and cash flow metrics

Total Assets

$123.08 million

Total Liabilities

$9.26 million

Operating Cash Flow

$0

Capital Expenditure

$485000

Dividend Payout Ratio

0%

Talis Biomedical Corp ended 2024 with $123.08 million in total assets and $0 in total liabilities. Its intangible assets were valued at $123.08 million while shareholder equity stood at $96.17 million.

Talis Biomedical Corp ended 2024 with $0 in deferred long-term liabilities, $9.26 million in other current liabilities, in common stock, $-510819000.00 in retained earnings and $0 in goodwill. Its cash balance stood at $98.20 million and cash and short-term investments were $98.20 million. The company’s total short-term debt was $2,736,000 while long-term debt stood at $0.

Talis Biomedical Corp’s total current assets stands at $101.97 million while long-term investments were $0 and short-term investments were $0. Its net receivables were $532000.00 compared to accounts payable of $2.49 million and inventory worth $1.01 million.

In 2024, Talis Biomedical Corp's operating cash flow was $0 while its capital expenditure stood at $485000.

Comparatively, Talis Biomedical Corp paid $0 in dividends in 2024.

Other key metrics

Current Trading Price

$6.45

52-Week High

$14.25

52-Week Low

$5.8

Analyst Target Price

$5.25

Talis Biomedical Corp stock is currently trading at $6.45 per share. It touched a 52-week high of $14.25 and a 52-week low of $14.25. Analysts tracking the stock have a 12-month average target price of $5.25.

Its 50-day moving average was $7.07 and 200-day moving average was $7.65 The short ratio stood at 1.15 indicating a short percent outstanding of 0%.

Around 844.7% of the company’s stock are held by insiders while 4383.5% are held by institutions.